PPP1R14C: A Potential Drug Target for Breast Cancer (G81706)

Target Name: PPP1R14C

NCBI ID: G81706

PPP1R14C

PPP1R14C: A Potential Drug Target for Breast Cancer

Breast cancer is a leading cause of cancer-related deaths in women worldwide. The development and progression of breast cancer can be highly unpredictable and can often lead to a poor prognosis. Therefore, identifying potential biomarkers and drug targets is crucial for improving the treatment outcomes of breast cancer patients. In this article, we will discuss PPP1R14C, a serologically defined breast cancer antigen (SDBA) identified by researchers as a potential drug target for breast cancer.

PPT1R14C: A Potential Drug Target for Breast Cancer

PPT1R14C is a transmembrane protein located in the periprogressive nuclear envelope (PNE) of breast epithelial cells. It is a glycoprotein with a molecular weight of approximately 180 kDa and a pre-fusion protein N-tertier domain. PPT1R14C is highly expressed in breast epithelial tissue and has been shown to be involved in various cellular processes, including cell adhesion, migration, and invasion.

In addition to its putative involvement in cellular processes, PPT1R14C has also been shown to play a role in breast cancer progression. For instance, researchers have shown that high expression of PPT1R14C was significantly associated with poor prognosis in patients with node-negative breast cancer. Additionally, overexpression of PPT1R14C has been shown to promote the growth and invasiveness of human breast cancer cells in a xenograft model.

PPT1R14C as a Drug Target

The potential drug targets for breast cancer are vast and include various oncogenic pathways. One such pathway is the PI3K/AKT signaling pathway, which is known to play a crucial role in the regulation of cell survival and proliferation. Activation of this pathway has been implicated in the development and progression of many types of cancer, including breast cancer.

In the context of breast cancer, PPT1R14C has been shown to be involved in the PI3K/AKT signaling pathway. For instance, researchers have shown that overexpression of PPT1R14C led to increased AKT signaling activity and a reduction in cell proliferation. Additionally, they have found that PPT1R14C overexpression was associated with poor prognosis in patients with node-negative breast cancer, which is consistent with the idea that PPT1R14C may play a role in breast cancer progression.

Another potential drug target for breast cancer is the TGF-灏? pathway, which is involved in cell growth, angiogenesis, and metastasis. Activation of this pathway has been implicated in the development and progression of many types of cancer, including breast cancer.

PPT1R14C has also been shown to be involved in the TGF-灏? pathway. For instance, researchers have shown that overexpression of PPT1R14C led to increased TGF-灏? signaling activity and a reduction in cell proliferation. This suggests that PPT1R14C may play a negative role in the regulation of TGF-灏? signaling, which could be a potential drug target for breast cancer.

Conclusion

In conclusion, PPP1R14C is a potential drug target for breast cancer due to its involvement in the PI3K/AKT and TGF-灏? signaling pathways. Further research is needed to fully understand the role of PPT1R14C in breast cancer progression and to identify potential small molecules or antibodies that can inhibit its activity. By doing so, we may be able to improve the treatment outcomes for breast cancer patients.

Protein Name: Protein Phosphatase 1 Regulatory Inhibitor Subunit 14C

Functions: Inhibitor of the PP1 regulatory subunit PPP1CA

The "PPP1R14C Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PPP1R14C comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets